Drug Trial Radar · NCT07129473
Hyperemesis Gravidarum Risk Reduction With Metformin
Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
224
Planned (sponsor's estimate)
Start
Jul 13, 2026
Primary completion
Mar 2031
Study completion Mar 2031
Sponsor
- Lead sponsor
- University of Southern CaliforniaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Morning Sickness & HG Clinic
- First posted
- Aug 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate whether daily oral metformin extended-release (metformin-XR), taken prior to and in early pregnancy, can reduce the risk and severity of Hyperemesis Gravidarum (HG), a severe nausea and vomiting condition in pregnancy, in individuals aged 18-49 who have experienced HG in a previous pregnancy and are trying to conceive. Researchers also aim to better understand which individuals may respond well - or poorly - to metformin based on biological and clinical characteristics. The main questions this study aims to answer are: 1. Is metformin-XR well-tolerated when taken by non-pregnant individuals who have had HG in a previous pregnancy and are currently trying to conceive? 2. How safe and tolerable is metformin-XR when taken at increasing doses over an 8-week titration period and continued through early pregnancy (or for up to 12 months after reaching maintenance dose if pregnancy does not occur)? 3. Among those who become pregnant during the study, does pre-pregnancy metformin-XR use reduce the risk of HG coming back and lower the severity of nausea and vomiting symptoms? 4. How does pre-pregnancy metformin-XR use affect pregnancy outcomes, postpartum health, and newborn health and development? 5. Are there specific genetic, biomarker, demographic, or clinical features that predict whether someone is likely to benefit from metformin-XR or experience side effects that lead them to stop taking it? Researchers will compare a metformin treatment group to a survey-only group (comparator, no study drug) to see if metformin-XR is associated with improved outcomes, including reduced HG recurrence and better maternal and neonatal health indicators. Participants will: Complete online questionnaires before pregnancy, during early pregnancy, and postpartum (Treatment group only) Take daily metformin-XR and attend three brief study visits (Treatment group only) Undergo blood draws at specified timepoints to assess safety and biological response
Conditions
- Hyperemesis Gravidarum
Interventions
Metformin Extended Release Oral TabletDrug
Participants in the Treatment Arm will receive oral extended-release metformin (metformin-XR) once daily with an evening meal starting prior to conception. Daily dosing will begin at 500 mg and increase gradually over an 8-week period (+500 mg every 2 weeks, as tolerated, with increases, holds, or reductions based on symptom severity) to a maximum dose of 2,000 mg. Treatment at highest tolerated dose will continue until 2 weeks after positive pregnancy test or 12 months after cessation of birth control/contraceptive device. Participants will attend 3 clinic visits and provide blood samples at baseline, after dose escalation, and during early pregnancy to assess biomarker levels and genetic characteristics. Daily dosing, adherence, and side effects are recorded via MyCap; clinical visits include vital signs, PUQE-24/HELP scores, and blood draws. Postpartum surveys include a metformin treatment \& HG outcomes survey (REDCap) and additional measures (PES, MAPP-QOL, EPDS, PSAS, and ASQ-3).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adherence to Escalating Doses of Metformin-XRTime frame: Baseline to 8 weeks after treatment initiation
- Tolerability and Safety of Metformin-XRTime frame: Baseline through treatment completion (up to 12 months after maintenance dose following cessation of birth control/contraceptive device or 2 weeks after confirmed pregnancy, whichever comes first)
- Hyperemesis Gravidarum (HG) Recurrence and SeverityTime frame: From confirmed pregnancy through 12 weeks of gestation
- Pregnancy & Neonatal Outcomes: Incidence of Pregnancy ComplicationsTime frame: From confirmed pregnancy through delivery
- Pregnancy & Neonatal Outcomes: Delivery CharacteristicsTime frame: At delivery
- Pregnancy & Neonatal Outcomes: Assessment of Peripartum EventsTime frame: From confirmed pregnancy to 6 months postpartum
- Pregnancy & Neonatal Outcomes: Maternal Postpartum DepressionTime frame: From birth to 6 months postpartum
- Pregnancy & Neonatal Outcomes: Maternal Postpartum AnxietyTime frame: From birth to 6 months postpartum
- Pregnancy & Neonatal Outcomes: Maternal Postpartum Quality of LifeTime frame: From birth to 6 months postpartum
- Pregnancy & Neonatal Outcomes: Neonatal Health StatusTime frame: At delivery
- Pregnancy & Neonatal Outcomes: Child Developmental StatusTime frame: From birth to 6 months postpartum (with optional follow up until the end of the 5-year study period)
- Indicators of Metformin Response: Genetic FactorsTime frame: Once at baseline
- Indicators of Metformin Response: Circulating Biomarker LevelsTime frame: Once at baseline, once when participant reaches highest tolerated metformin dose (up to week 8), and once at pregnancy confirmation in participants who conceive
- Indicators of Metformin Response: Demographic CharacteristicsTime frame: At baseline
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Morning Sickness & HG Clinic
Birmingham, Alabama · Not yet recruiting
University of Southern California - Keck School of Medicine
Los Angeles, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.